Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$86000.0.

  • Altimmune's Other Non Operating Income fell 57777.78% to -$86000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$45000.0, marking a year-over-year increase of 1000.0%. This contributed to the annual value of $48000.0 for FY2024, which is 7108.43% down from last year.
  • Altimmune's Other Non Operating Income amounted to -$86000.0 in Q3 2025, which was down 57777.78% from -$92000.0 recorded in Q2 2025.
  • In the past 5 years, Altimmune's Other Non Operating Income ranged from a high of $118000.0 in Q4 2024 and a low of -$286000.0 during Q3 2021
  • Its 5-year average for Other Non Operating Income is -$18684.2, with a median of $15000.0 in 2025.
  • Data for Altimmune's Other Non Operating Income shows a peak YoY increase of 54232.73% (in 2021) and a maximum YoY decrease of 107884.87% (in 2021) over the last 5 years.
  • Altimmune's Other Non Operating Income (Quarter) stood at -$81000.0 in 2021, then crashed by 167.9% to -$217000.0 in 2022, then soared by 109.22% to $20000.0 in 2023, then soared by 490.0% to $118000.0 in 2024, then tumbled by 172.88% to -$86000.0 in 2025.
  • Its Other Non Operating Income stands at -$86000.0 for Q3 2025, versus -$92000.0 for Q2 2025 and $15000.0 for Q1 2025.